BR0213977A - Derivados de piridina como ligantes de receptores de nmda - Google Patents

Derivados de piridina como ligantes de receptores de nmda

Info

Publication number
BR0213977A
BR0213977A BR0213977-4A BR0213977A BR0213977A BR 0213977 A BR0213977 A BR 0213977A BR 0213977 A BR0213977 A BR 0213977A BR 0213977 A BR0213977 A BR 0213977A
Authority
BR
Brazil
Prior art keywords
hydrogen
lower alkyl
nmda receptor
pyridine derivatives
compounds
Prior art date
Application number
BR0213977-4A
Other languages
English (en)
Inventor
Alexander Alanine
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0213977A publication Critical patent/BR0213977A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE PIRIDINA COMO LIGANTES DE RECEPTORES DE NMDA". A presente invenção refere-se a compostos de fórmulas (IA) ou (IB) onde R^ 1^' e R^ 2^ são independentemente um do outro hidrogênio, alquila inferior, -(CH~ 2~)~ n~-OH, -(CH~ 2~)~ n~-N(R^ 6^)~ 2~, -NR^ 6^C(O)C(O)O-alquila inferior, -NR^ 6^- (CH~ 2)~ n~-OH, -NR^ 6^C(O)-alquila inferior, -NH-benzila ou NR^ 6^C(O)-(CH~ 2~)~ n~-OH; R^ 6^ é independentemente um do outro hidrogênio ou alquila inferior; R<39> é hidrogênio ou alquila inferior; R^ 3^ é hidrogênio ou amino; R^ 4^ é hidrogênio ou alquila inferior; R^ 5^ é hidrogênio ou halogênio; ou R^ 1^ e R<39>^ poderão ser juntamente com os átomos de carbono aos quais se ligam o grupo -(CH~ 2~)~ 4~-; ou R^ 2^ e R^ 3^ poderão ser juntamente com os átomos de carbono aos quais se ligam o grupo -N(R^ 6^)-CH~ 2~-O-CH~ 2~-; n é 0, 1, 2 ou 3; e a sais de adição de ácidos farmaceuticamente aceitáveis desses compostos. Mostrou-se que esses compostos apresentam uma boa afinidade ao receptor de NMDA e poderão portanto ser usados para o tratamento de doenças relacionadas com esse receptor.
BR0213977-4A 2001-11-09 2002-11-02 Derivados de piridina como ligantes de receptores de nmda BR0213977A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01126467 2001-11-09
PCT/EP2002/012240 WO2003040128A1 (en) 2001-11-09 2002-11-02 Pyridine derivatives as nmda receptor ligands

Publications (1)

Publication Number Publication Date
BR0213977A true BR0213977A (pt) 2004-08-31

Family

ID=8179179

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213977-4A BR0213977A (pt) 2001-11-09 2002-11-02 Derivados de piridina como ligantes de receptores de nmda

Country Status (16)

Country Link
US (1) US6831087B2 (pt)
EP (1) EP1448547B1 (pt)
JP (1) JP4188837B2 (pt)
KR (1) KR100589995B1 (pt)
CN (1) CN100516061C (pt)
AR (1) AR037221A1 (pt)
AT (1) ATE293619T1 (pt)
AU (1) AU2002351816B8 (pt)
BR (1) BR0213977A (pt)
CA (1) CA2467973C (pt)
DE (1) DE60203820T2 (pt)
ES (1) ES2240829T3 (pt)
MX (1) MXPA04004308A (pt)
PL (1) PL369544A1 (pt)
RU (1) RU2303037C2 (pt)
WO (1) WO2003040128A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2205599B1 (de) 2007-10-18 2012-06-06 Boehringer Ingelheim International GmbH Cgrp-antagonisten
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
CA2705599A1 (en) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
US8829006B2 (en) 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
EA014100B1 (ru) * 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
RU2438672C1 (ru) * 2010-04-30 2012-01-10 Общество с ограниченной ответственностью "Клевер Фарм" Агент, проявляющий свойства активатора когнитивных функций (варианты)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
EP1080074B1 (de) * 1998-05-25 2006-11-08 Abbott GmbH & Co. KG Heterocyclische substituierte Amide, deren Herstellung und Verwendung
US6440995B1 (en) * 1999-10-01 2002-08-27 Hoffman-La Roche Inc. Quinolin-4-yl derivatives
EP1088818B1 (en) 1999-10-01 2004-11-03 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives

Also Published As

Publication number Publication date
ATE293619T1 (de) 2005-05-15
PL369544A1 (en) 2005-05-02
AU2002351816B8 (en) 2008-04-03
DE60203820T2 (de) 2006-02-23
ES2240829T3 (es) 2005-10-16
CN1585762A (zh) 2005-02-23
JP2005513004A (ja) 2005-05-12
EP1448547B1 (en) 2005-04-20
DE60203820D1 (de) 2005-05-25
EP1448547A1 (en) 2004-08-25
KR20050042252A (ko) 2005-05-06
CA2467973C (en) 2009-09-01
JP4188837B2 (ja) 2008-12-03
CN100516061C (zh) 2009-07-22
AR037221A1 (es) 2004-10-27
MXPA04004308A (es) 2004-08-11
KR100589995B1 (ko) 2006-06-19
WO2003040128A1 (en) 2003-05-15
US6831087B2 (en) 2004-12-14
RU2303037C2 (ru) 2007-07-20
CA2467973A1 (en) 2003-05-15
AU2002351816B2 (en) 2008-03-06
RU2004117595A (ru) 2006-01-10
US20030119870A1 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
BR0213977A (pt) Derivados de piridina como ligantes de receptores de nmda
BR0210538A (pt) Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
AU4954097A (en) 2-pyrimidineamine derivatives and processes for their preparation
DK0870768T3 (da) Azaindol-ethylaminderivater som nikotinacetylcholinreceptor-bindingsmidler
FI92582B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten kinoksaliinijohdannaisten valmistamiseksi
DE69823648D1 (de) 1-phenyl-4-benzylpiperazine: spezifische liganden für den dopamin rezeptor (d4)
Schroeder et al. Identification of pyrrolo [2, 1-f][1, 2, 4] triazine-based inhibitors of Met kinase
HUP0100865A2 (hu) Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
NO973243L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av gynekologiske sykdommer
HUP9901616A1 (hu) Új benzofuranon-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO992676L (no) 1,4-diazabicyklo[2,2,2]okt-2-ylmetylderivater, deres fremstilling og terapeutiske anvendelse
HUP0102057A2 (hu) Benzofuroxánszármazékok alkalmazása angina pectoris kezelésében
BR0214488A (pt) Derivados de benzotiazol
BR0115480A (pt) Derivados de pirimidina
Meyer et al. Synthesis and In Vitro Evaluation of 2‐Aminoquinazolin‐4 (3H)‐one‐Based Inhibitors for tRNA‐Guanine Transglycosylase (TGT)
HUP0203603A2 (hu) Új IL-8 receptor antagonista hatású indolszármazékok és ezeket tartalmazó gyógyszerkészítmények
YU72000A (sh) Kompleks platine, njegovo dobijanje i terapeutska primena
WO2000075150A1 (fr) Ligands du recepteur ip¿3?
CY1108396T1 (el) Μη νουκλεοζιτικοι αναστολεις της αναστροφης μεταγραφασης ως ανταγωνιστες του κυτταρικου πολλαπλασιασμου και επαγωγεις της διαφοροποιησεως των κυτταρων
ATE219486T1 (de) Trizyklische indol-2-carbonsäure derivate als selektive nmda rezeptor antagonisten
Fierro et al. Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: Insights from molecular modeling studies
BR0107404A (pt) Derivados de indol que atuam como antagonistas do receptor mcp-1
YU74601A (sh) POSTUPAK ZA DOBIJANJE (S-(R*,S*)]-p-[[[1-OkSO-3-(4-PIPERIDINIL)PROPIL]-3-PIPERIDINIL]KARBONIL]AMINO]-3-PIPERIDINPROPIONSKE KISELINE I NJENIH DERIVATA
HUP9900642A2 (hu) Símaizom sejtburjánzást gátló 2-szubsztituált benzimidazolszármazékok, eljárás előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
BR0308890A (pt) Composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 9A ANUIDADE.